FR2296429B1 - - Google Patents

Info

Publication number
FR2296429B1
FR2296429B1 FR7539814A FR7539814A FR2296429B1 FR 2296429 B1 FR2296429 B1 FR 2296429B1 FR 7539814 A FR7539814 A FR 7539814A FR 7539814 A FR7539814 A FR 7539814A FR 2296429 B1 FR2296429 B1 FR 2296429B1
Authority
FR
France
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
FR7539814A
Other languages
French (fr)
Other versions
FR2296429A1 (en
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Plasmesco AG
Original Assignee
Plasmesco AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Plasmesco AG filed Critical Plasmesco AG
Publication of FR2296429A1 publication Critical patent/FR2296429A1/en
Application granted granted Critical
Publication of FR2296429B1 publication Critical patent/FR2296429B1/fr
Granted legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/06Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Inorganic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
FR7539814A 1975-01-02 1975-12-26 PROCESS FOR IMPROVING THE TOLERANCE TO INTRAVENOUS INJECTION OF GAMMAGLOBULIN Granted FR2296429A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE2500076A DE2500076C3 (en) 1975-01-02 1975-01-02 Process for the production of intravenously tolerated gamma globulins

Publications (2)

Publication Number Publication Date
FR2296429A1 FR2296429A1 (en) 1976-07-30
FR2296429B1 true FR2296429B1 (en) 1978-12-01

Family

ID=5935911

Family Applications (1)

Application Number Title Priority Date Filing Date
FR7539814A Granted FR2296429A1 (en) 1975-01-02 1975-12-26 PROCESS FOR IMPROVING THE TOLERANCE TO INTRAVENOUS INJECTION OF GAMMAGLOBULIN

Country Status (20)

Country Link
JP (1) JPS5512001B2 (en)
AT (1) AT344883B (en)
AU (1) AU505416B2 (en)
BE (1) BE837211A (en)
CA (1) CA1058075A (en)
DD (1) DD121875A5 (en)
DE (1) DE2500076C3 (en)
DK (1) DK144679C (en)
EG (1) EG11987A (en)
ES (1) ES443982A1 (en)
FR (1) FR2296429A1 (en)
GB (1) GB1495159A (en)
IE (1) IE43449B1 (en)
IL (1) IL48766A (en)
IN (1) IN143525B (en)
NL (1) NL179824C (en)
PL (1) PL99599B1 (en)
SE (1) SE437470B (en)
SU (1) SU576898A3 (en)
ZA (1) ZA758050B (en)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2604759C2 (en) * 1976-02-07 1983-06-01 SCHURA Blutderivate GmbH & Co KG, 4150 Krefeld Method of Obtaining IV Compatible Gamma Globulins
JPS6016406B2 (en) * 1976-08-06 1985-04-25 マイヤ−、ル−イス、コ−バル Method for producing intravenously administrable gamma globulin and gamma globulin prepared thereby
US4124576A (en) * 1976-12-03 1978-11-07 Coval M L Method of producing intravenously injectable gamma globulin
GB1603244A (en) * 1977-05-20 1981-11-18 Max Planck Gesellschaft Medicaments for the suppression of pathological processes
JPS5822085B2 (en) * 1977-07-19 1983-05-06 株式会社ミドリ十字 Intravenous gamma globulin preparations
AT359641B (en) * 1978-09-19 1980-11-25 Immuno Ag METHOD FOR PRODUCING AN INTRAVENOUS ADMINISTRABLE ANTIBODY-CONTAINING IMMUNOGLOBULIN PREPARATE
EP0019403B1 (en) * 1979-05-10 1985-07-31 American Hospital Supply Corporation Hydroxyalkyl-starch drug carrier
US4396608A (en) * 1981-08-24 1983-08-02 Cutter Laboratories Intravenously injectable immune serum globulin
DE3271181D1 (en) * 1982-02-08 1986-06-19 Schweiz Serum & Impfinst Intravenously administrable human immunoglobuline and process for its preparation
US4482483A (en) * 1983-04-06 1984-11-13 Armour Pharmceutical Company Composition of intravenous immune globulin
SE8302483L (en) * 1983-05-02 1984-11-03 Pharmacia Ind PROCEDURE FOR PURIFICATION OF BIOLOGICALLY ACTIVE SUBSTANCES
US5945098A (en) * 1990-02-01 1999-08-31 Baxter International Inc. Stable intravenously-administrable immune globulin preparation
DE19907257A1 (en) * 1999-02-21 2000-09-14 Bernd Horst Meier Means for controlling the diffusion of injection solutions
DE10040707A1 (en) * 2000-08-17 2002-03-14 Braun Melsungen Ag Injectable aqueous medicament, containing colloid, e.g. hydroxyethyl starch, to modulate mobility, diffusion, pharmacokinetic and electrophoretic properties of active agent and improve effectiveness
DE10303974A1 (en) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid β (1-42) oligomers, process for their preparation and their use
US8497072B2 (en) 2005-11-30 2013-07-30 Abbott Laboratories Amyloid-beta globulomer antibodies
PL2289909T3 (en) 2005-11-30 2015-04-30 Abbvie Inc Screening method, process for purifying of non-diffusible a-beta oligomers, selective antibodies against said non-diffusible a-beta oligomers and a process for manufacturing of said antibodies
US8455626B2 (en) 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
WO2008104386A2 (en) 2007-02-27 2008-09-04 Abbott Gmbh & Co. Kg Method for the treatment of amyloidoses
US8987419B2 (en) 2010-04-15 2015-03-24 AbbVie Deutschland GmbH & Co. KG Amyloid-beta binding proteins
CA2808187A1 (en) 2010-08-14 2012-02-23 Abbvie Inc. Amyloid-beta binding proteins

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE348942B (en) * 1970-06-02 1972-09-18 Statens Bakteriologiska Labor
DE2234069A1 (en) * 1971-07-16 1973-02-08 South African Inventions METHOD OF MANUFACTURING A PURIFIED GAMMA GLOBULIN
IL43643A (en) * 1972-11-27 1976-10-31 Baxter Laboratories Inc Method for production of gamma globulin
JPS49101516A (en) * 1973-01-13 1974-09-25

Also Published As

Publication number Publication date
AT344883B (en) 1978-08-10
JPS5512001B2 (en) 1980-03-29
DE2500076B2 (en) 1979-02-22
FR2296429A1 (en) 1976-07-30
AU8792175A (en) 1977-07-14
ES443982A1 (en) 1977-07-16
ZA758050B (en) 1976-12-29
IL48766A (en) 1979-11-30
GB1495159A (en) 1977-12-14
NL179824C (en) 1986-11-17
AU505416B2 (en) 1979-11-22
DK144679B (en) 1982-05-10
SE7514388L (en) 1976-07-05
BE837211A (en) 1976-06-30
IN143525B (en) 1977-12-17
EG11987A (en) 1981-12-31
JPS5191321A (en) 1976-08-10
NL7514627A (en) 1976-07-06
DK144679C (en) 1982-10-11
SU576898A3 (en) 1977-10-15
IE43449B1 (en) 1981-02-25
IL48766A0 (en) 1976-02-29
PL99599B1 (en) 1978-07-31
DE2500076A1 (en) 1976-07-08
CA1058075A (en) 1979-07-10
IE43449L (en) 1976-07-02
DK584375A (en) 1976-07-03
ATA981675A (en) 1977-12-15
DE2500076C3 (en) 1982-11-18
DD121875A5 (en) 1976-09-05
NL179824B (en) 1986-06-16
SE437470B (en) 1985-03-04

Similar Documents

Publication Publication Date Title
FR2296429B1 (en)
CH597924A5 (en)
BG22009A1 (en)
BG22029A1 (en)
BG22137A1 (en)
BG22756A1 (en)
BG22941A1 (en)
BG23083A1 (en)
BG23151A1 (en)
BG23350A1 (en)
CH1667475A4 (en)
CH577919A5 (en)
CH584450A5 (en)
CH588045A5 (en)
CH588052A5 (en)
CH588789A5 (en)
CH589979A5 (en)
CH590081A5 (en)
CH590107A5 (en)
CH590628A5 (en)
CH590986A5 (en)
CH593137A5 (en)
CH593798A5 (en)
CH593807A5 (en)
CH594270A5 (en)

Legal Events

Date Code Title Description
TP Transmission of property